Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
-
DNA tests and funerals in Nepal, a week after deadly floods
-
Fernandez 'didn't hesitate' over record Man City move
-
Iran threatens tougher strategy after US strikes kill 4 at wedding
-
Dutch shift 86 tonnes of gold from US, Canada to UK
-
Chevron unveils deal to double Venezuela venture output in 5 years
-
Nepal floods should mobilise climate action: UN green fund chief
-
Uganda names its oil 'Pearl Sweet' as it prepares for first exports
-
Nvidia boss presses G20 ministers to build AI infrastructure
-
Tiger Woods driver's license suspended for five years after crash
-
Liminal Launches Liminal Prime for Institutional OTC and Stablecoin Liquidity
-
Germany probes latest sabotage attacks on power grid
-
10 missing as cargo ship sinks after collision off Istanbul
-
Wall Street stocks mixed as energy prices, bond yields turn lower
-
30 years on, 'Tomb Raider' reboot sees Lara Croft through a 'modern lens'
-
Tiger Woods pleads guilty to reckless driving, license suspended
-
King Charles, Macron to view Bayeux Tapestry as French leader starts UK visit
-
Missing passengers likely went down with sunken ferry: N.Cyprus official
-
George Clooney says US run by 'least qualified people'
-
Premier League clubs splash cash to smash transfer record
-
China's Xi urges against Mideast interference in rare Egypt visit
-
Melting glaciers an 'immediate' climate risk: author of UN report
-
Venice to roll out red carpet for 'lucky' Clooney on opening night
-
Folarin Balogun's move to Everton collapses
-
'Humiliated' Aubameyang quits Gabon national team
-
Pacific islands to face food shortages over global warming: scientists
-
France sees limited economic hit from drought, heatwaves
-
Venice jury head Maggie Gyllenhaal questions lack of women directors
-
Bus crash in Egypt's Sinai kills 22, including 10 Jordanians
-
Stocks drop, bond yields rally on Mideast flare-up
-
UN says world must navigate 'reality' of 1.5C overshoot
-
China expands Egypt investments in first Xi visit in a decade
-
Taliban govt defends ban on protest, citing Islamic law
-
Messi departure leaves Argentina facing rebuild after golden era
-
10 missing as Turkish cargo ship sinks after collision off Istanbul
-
Ourbit SuperCEX Launches "Cosmic Wheel Season 3. Oracle Realm" on September 2 with 3M USDT Prize Pool
-
easyMarkets Expands Commodity Offering with 24/7 Gold, Silver and Oil Trading
-
Ebola death toll passes 3,000 in DR Congo: official data
-
Australia defends Pacific climate meeting despite doubts on attendance
-
Hong Kong democracy activist Wong pleads guilty to foreign collusion
-
Iran attacks US sites after American strikes, wedding deaths
-
World record prize winner Romantic Warrior retires from horse racing
-
Stocks drop, yields at three-decade highs on Mideast flare-up
-
5,000 US sailors arrive in Thailand after months at sea
-
EU summons Russian envoy, eyes sanctions after Germany drone 'attack'
-
Joshua Wong, Hong Kong's pro-democracy poster child
-
Stocks drop as yields and oil prices spike on Mideast flare-up
-
Nepal tunnel rescuers seek trapped workers but hit dead ends
-
Cricketers to get best rooms at Asian Games, says Japan chief
-
Zverev wins wild five-setter, Rybakina and Gauff ease through at US Open
-
Zverev out-lasts Sonego in wild five-setter to advance at US Open
NYSE - LSE
Champions Oncology Obtains Radioactive Materials License to Advance Comprehensive Radiotherapeutic Studies In-House
HACKENSACK, NJ / ACCESS Newswire / April 28, 2025 / Champions Oncology (NASDAQ:CSBR), a leader in translational oncology research, has been granted a license to use radioactive materials in preclinical studies. This approval allows in-house work utilizing a variety of clinically relevant radionuclides, significantly expanding the organization's capabilities in the development and assessment of targeted radiotherapeutics.
Through this license, Champions Oncology is now uniquely positioned to integrate under one roof radionuclide-based therapeutic testing with the most clinically relevant bank of patient derived xenograft (PDX) models.
"This license marks a significant milestone in our capability to support biopharmaceutical partners in developing next-generation radiotherapeutics," stated Ronnie Morris, CEO of Champions Oncology. "By integrating this expertise with our well-characterized PDX platform, we are uniquely positioned to drive the advancement of radiopharmaceutical development with unparalleled translational precision."
This comprehensive program will support drug developers across a range of modalities, including antibody-radionuclide conjugates and peptide receptor radionuclides.
For partnership inquiries or to learn more, please contact us at https://www.championsoncology.com/contact-us.
About Champions Oncology
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Rachel Bunting, MS, MBA
VP, Global Marketing
[email protected]
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
Ch.Campbell--AT